Picard Medical heads into a pivotal week with its lending market flipping dramatically — from near-total borrow exhaustion to abundant availability — as a dilutive equity offering and fresh earnings results reshape the short thesis.
The most striking development in PMI this week is how rapidly the borrow market has unwound. Two weeks ago the stock was in a genuine squeeze: borrow availability had collapsed to near-zero, with utilization peaking above 97% on May 4–5. That meant almost no shares remained available to lend — a classic setup for forced short covering. Then came the May 5 dilutive offering: Picard priced 16.67 million new shares at $0.30, a sharp discount to where the stock was trading. The share count surge flooded the lending pool. By May 14, availability had opened dramatically and utilization had fallen all the way to 6.4%. What was an extremely tight borrow market is now essentially loose.
Cost to borrow tells the same story, but with a lag. CTB peaked above 317% in early May — one of the most punishing borrow rates in the small-cap health care space — and has since eased to around 161%. That is still an elevated rate by any standard, reflecting residual demand for the short versus a structurally changed float. Short interest itself dropped 53% on May 14 alone, falling to roughly 644,000 estimated shares from over 1.5 million earlier in the week. The short score, which had climbed to nearly 75 on May 5, has pulled back sharply to 44.9 — the lowest reading of the past two weeks. The squeeze pressure has dissipated, and the positioning data reflects it.
Ownership concentration is the other angle worth watching. Hunniwell Lake Ventures holds 52.7% of shares. Sindex SSI Financing controls another 10.6%. Together, two entities own nearly two-thirds of the company. With a public float that small to begin with, the May offering's addition of 16.7 million shares at $0.30 into a stock now trading at $0.16 is a material overhang. The stock has fallen 83% in a single month and 23% in the past week alone, closing at $0.16 on May 15 — well below the offering price.
The fundamental picture is mixed but improving at the margin. Q1 2026 results released May 15 showed revenue of $1.15 million, up from $620,000 a year earlier, and the net loss per share narrowed sharply to $0.10 from $0.80. The company is still burning cash, and the full-year 2025 results showed a net loss of $27 million on revenue under $5 million. A follow-on equity offering of up to $20 million was filed in late April, adding further dilution risk ahead. The next scheduled event is May 22, with no analyst coverage active on the name.
The setup heading into next week is therefore less about short positioning — which has deflated — and more about whether the stock can stabilise above the recent offering price, and what the $20 million follow-on filing ultimately means for the share count.
See the live data behind this article on ORTEX.
Open PMI on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
